AI-generated summary
The authors systematically reviewed 28 studies published between 2010 and 2025 on energy-based devices and intralesional injections for morphea and systemic sclerosis, covering 732 patients. They report positive therapeutic outcomes in most included studies and no life-threatening adverse events. The mix of study designs and the limited evidence base mean the findings are preliminary, and further trials are needed.
- Participants
- 732
- Studies included
- 28
- Who or what was studied
- Patients with morphea or systemic sclerosis (ages 6 to 70; 84.4% women)
- Wavelengths
- 850, 660, 405 nm
- Limits stated in the abstract
- The abstract notes limited evidence, a mix of study designs (many non-randomized or retrospective), varied follow-up of 5 days to 37 months, and calls for further clinical trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850 nm, 660 nm, 405 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Systematic review, Laser, Photodynamic therapy, Inflammation, Phototherapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.